

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
13 November 2003 (13.11.2003)

PCT

(10) International Publication Number
WO 03/093260 A1(51) International Patent Classification⁷: C07D 401/06,
A61K 31/473

(21) International Application Number: PCT/US03/13220

(22) International Filing Date: 29 April 2003 (29.04.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/376,395 30 April 2002 (30.04.2002) US(71) Applicant (for all designated States except BB, US):
BIOGAL GYOGYSZERGYAR RT. [HU/HU]; Pallagi
13, H-4042 Debrecen (HU).(71) Applicant (for BB only): TEYA PHARMACEUTICALS
USA, INC. [US/US]; 1090 Horsham Road, P.O. Box 1090,
North Wales, PA 19454-1090 (US).


(72) Inventors; and

(75) Inventors/Applicants (for US only): ARONHIME, Ju-
dith [IL/IL]; Rehov Harav Maor Josef 5a, 76217 Rehovot
(IL). MOLNAR, Sandor [HU/HU]; Tocskert ter 2, IX/71,
H-4031 Debrecen (HU). SZABO, Csaba [HU/HU]; Tozser
u.1, H-4031 Debrecen (HU). MESZAROS SOS, Erzsébet[HU/HU]; u.3 11/32 Vargakert, H-4031 Debrecen (HU).
SALYI, Szabolcs [HU/HU]; Derek ut., 151. Fsz.1, H-4031
Debrecen (HU). TAMAS, Tivadar [HU/HU]; Budai Nagy
Antal u.37, H-4034 Debrecen (HU).(74) Agents: BRAINARD, Charles, R. et al.; Kenyon &
Kenyon, One Broadway, New York, NY 10004-1050 (US).(81) Designated States (national): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD,
SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US,
UZ, VC, VN, YU, ZA, ZM, ZW.(84) Designated States (regional): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO,
SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM,
GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

[Continued on next page]

(54) Title: NOVEL CRYSTAL FORMS OF ONDANSETRON, PROCESSES FOR THEIR PREPARATION, PHARMACEUTI-
CAL COMPOSITIONS CONTAINING THE NOVEL FORMS AND METHODS FOR TREATING NAUSEA USING THEM

WO 03/093260 A1

(57) Abstract: Ondansetron crystalline Forms A and B are useful in the treatment of nausea and vomiting. Form B has uniquely high melting point of about 244 °C and both forms are stable against thermally induced polymorphic transition from 30 °C up to their melting points.



For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

NOVEL CRYSTAL FORMS OF ONDANSETRON,
PROCESSES FOR THEIR PREPARATION,
PHARMACEUTICAL COMPOSITIONS CONTAINING THE NOVEL
FORMS AND METHODS FOR TREATING NAUSEA USING THEM

CROSS REFERENCE TO RELATED APPLICATION


This application claims the benefit under 35 U.S.C. §1.119(e) of Provisional Application Serial No. 60/376,395, filed April 30, 2002, and is incorporated herein by reference.

FIELD OF THE INVENTION

The present invention relates to (±) 1,2,3,9-tetrahydro-9-methyl-3-[2-methyl-1H-imidazol-1-yl)methyl]-4H-carbazol-4-one (ondansetron). More particularly, it relates to a newly discovered high melting crystalline form of ondansetron, to a second newly discovered crystalline form, to processes for producing the new forms, to pharmaceutical compositions containing them and methods of treating nausea and vomiting using them.

BACKGROUND OF THE INVENTION

(±) 1,2,3,9-Tetrahydro-9-methyl-3-[2-methyl-1H-imidazol-1-yl)methyl]-4H-carbazol-4-one having the molecular structure



and formula C₁₈H₁₉N₃O is a selective 5-HT₃ receptor antagonist. It is a nitrogen-containing compound capable of existence in free base and salt forms. The free base is known by the generic name ondansetron. Ondansetron is useful for reducing nausea in patients undergoing chemotherapy. Grunberg, S.M.; Hesketh, P.J. "Control of Chemotherapy-Induced Emesis" *N. Engl. J. Med.* 1993, 329, 1790-96. It is approved

by the United States Food and Drug Administration for prophylactic treatment of nausea and vomiting associated with some cancer chemotherapy, radiotherapy and postoperative nausea and/or vomiting. Ondansetron is commercially available in orally disintegrating tablets under the trade name Zofran® ODT.

5 The present invention relates to the solid state physical properties of ondansetron. According to the *Merck Index* 6977 (12th ed., Merck & Co: Whitehouse Station, NJ 1996), ondansetron has a melting point (m.p.) range of 231-232°C.

 U.S. Patent No. 4,695,578 discloses several preparations of ondansetron. Commonly-assigned, co-pending U.S. Patent Application Serial No. [atty. ref. No. 10 2664/55602] also discloses a process for preparing ondansetron. The '578 patent and the [2664/55602] application are incorporated by reference in their entirety and, in particular, for their teachings how to synthesize ondansetron from commercially available and readily accessible starting materials.

 In Example 4 of the '578 patent, 1,2,3,9-tetrahydro-9-methyl-3-[2-methyl-1H- 15 imidazol-1-yl)methyl]-4H-carbazol-4-one was methylated at the 9-N position of the carbazol-4-one ring system with dimethylsulfate in N,N-dimethylformamide. Ondansetron forms as a solid in the reaction mixture. The isolated solid decomposes at 223-224°C.

 In Example 7 of the '578 patent, ondansetron was made by displacing 20 dimethylamine from 3-[(dimethylamino)methyl]-1,2,3,9-tetrahydro-9-methyl-4H-carbazol-4-one with 2-methylimidazole in water (although the mechanism of the reaction is not necessarily a simple substitution). The precipitated crude product with a melting point of 221-221.5°C was recrystallized from methanol to give ondansetron with a melting point of 231-232°C.

25 In Example 8 of the '578 patent, ondansetron was prepared by Michael-type addition of 2-methylimidazole to 1,2,3,9-tetrahydro-9-methyl-3-methylene-4H-carbazol-4-one. The product was recrystallized from methanol to give ondansetron that had a melting point of 232-234°C.

 In Example 18(ii) of the '578 patent, ondansetron with a melting point of 228- 30 229°C was prepared by substitution of 2-methylimidazole for chloride in 3-

(chloromethyl)-1,2,3,9-tetrahydro-9-methyl-4H-carbazol-4-one followed by column chromatography.

In Example 19 of the '578 patent, ondansetron with a melting point of 227-228.5°C was prepared by DDQ oxidation of 2,3,4,9-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-1H-carbazole maleate followed by column chromatography.

In Example 20 of the '578 patent, ondansetron with a melting point of 232-234°C was prepared by DDQ oxidation of 2,3,4,9-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-1H-carbazol-4-ol, followed by column chromatography.

In U.S. Patents Nos 4,983,621, 4,783,478 and 4,835,173, ondansetron was prepared as described in Example 7 of the '578 patent to produce crude and recrystallized ondansetron with identical melting point ranges.

In U.S. Patent No. 4,957,609, ondansetron was prepared by intramolecular palladium catalyzed coupling of 3-[2-iodophenyl)methylamino]-6-[(2-methyl-1H-imidazol-1-yl)methyl]-2-cyclohexen-1-one followed by column chromatography. The product decomposed at 215-216°C.

In U.S. Patent No. 4,739,072, ondansetron was prepared by a reaction involving zinc catalyzed cyclization of 6-[(2-methyl-1H-imidazol-1-yl)methyl]-3-(2-methyl-2-phenylhydrazino)-2-cyclohexen-1-one. Column chromatography yielded a product that melted at 216-218°C. Recrystallization of the chromatographed product from methanol gave ondansetron that melted in the range 227.5-228.5°C.

As the foregoing summary of some known processes for preparing ondansetron makes evident, the reported melting points of ondansetron vary widely, from 215°C with decomposition to as high as 234°C without decomposition, depending on how the ondansetron was prepared and isolated. It appears that ondansetron that has been crystallized from methanol in the past melted in a more narrow and consistent temperature range according to these reports (m.p. 227-234°C) than chromatographed material which appears to have melting points scattered over a wide range (215-234°C).

We have now discovered and characterized a novel high melting crystalline form of ondansetron and a second crystalline form that melts in a temperature more typical of ondansetron that has been produced by prior methods.

5 There is a need for new crystalline forms of ondansetron. The discovery of new crystalline forms of a pharmaceutical compound provides an opportunity to improve the performance characteristics of a pharmaceutical product. It enlarges the repertoire of materials that a formulation scientist has available for designing, for example, a pharmaceutical dosage form of a drug with a targeted release profile or other desirable characteristic.

10

SUMMARY OF THE INVENTION

A first aspect of the present invention is directed to crystalline Form B of ondansetron. Ondansetron Form B has a uniquely high melting point of $244 \pm 2^\circ\text{C}$ and is stable toward thermally induced polymorphic transition between 30°C and 180°C . Form B is identifiable by powder X-ray crystallography as well as its thermal properties. Form B can be prepared under controlled conditions by precipitation from certain alcohol solvents.

15 A second aspect of the present invention is directed to crystalline Form A of ondansetron which is readily identifiable by its powder X-ray diffraction pattern. Ondansetron Form A also is stable toward thermally induced polymorphic transition between 30°C and 180°C . Form A can be prepared under controlled conditions by precipitation from select organic solvents and mixtures of those organic solvents and water.

20 The present invention further provides pharmaceutical compositions comprising ondansetron Form A, ondansetron Form B and mixtures thereof.

Yet further, the present invention provides methods for treating and/or preventing nausea and vomiting with ondansetron Form A and ondansetron Form B. In particular ondansetron Forms A and B are useful for treating and/or preventing nausea and vomiting associated with surgery, emetogenic cancer chemotherapy and radiotherapy.

30

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 is a differential scanning calorimetry thermogram of ondansetron Form B.

FIG. 2 is a characteristic powder X-ray diffraction pattern of ondansetron Form B.

FIG. 3 is a differential scanning calorimetry thermogram of ondansetron Form A.

5 FIG. 4 is a characteristic powder X-ray diffraction pattern of ondansetron Form A.

DETAILED DESCRIPTION OF THE INVENTION

In a first aspect, the present invention provides a new thermally stable crystalline form of ondansetron, designated Form B. Form B has been characterized
10 by powder X-ray diffraction ("PXRD") analysis, and thermal methods including differential scanning calorimetry ("DSC") and thermogravimetric analysis ("TGA"). PXRD patterns and differential thermograms are provided as figures. Where relevant, TGA results are discussed in the written portion of the disclosure.

Referring to FIG. 1, the differential thermogram of ondansetron Form B
15 demonstrates the unique thermal stability of this crystalline form. FIG. 1 possesses a sharp melting endotherm with a maximum at 244°C. Variation in the temperature of the maximum endotherm of melting obtained from like samples of Form B analyzed on different commercial calorimeters using the same heating rate should be considerably less than $\pm 2^\circ\text{C}$. However, capillary melting points typically are not
20 measured or recorded with accurately determined heating rates. Different heating rates combined with thermal inertia can cause the capillary melting point to deviate from the true melting point of a sample. Thus, it is considered that ondansetron that produces a thermal analysis result, e.g. measured melting point, maximum melting endotherm, inflection point in heat absorption curve and the like, that is indicative of
25 melting at $244 \pm 2^\circ\text{C}$ is consistent with its identity as Form B. The magnitude of the melting endotherm was estimated to be 140.11 J g^{-1} but overlap with another endotherm prevented accurate determination of the heat of fusion.

Above the melting endotherm and partially overlapping it, there is a broad endotherm caused by volatilization or chemical decomposition of ondansetron. At
30 temperatures below the melting endotherm, the differential thermogram is flat. This

characteristic is consistent with an absence of a polymorphic transition before melting. Therefore, Form B appears to be stable toward thermally induced polymorphic transitions from 30°C to 180°C, although transitions that are neither detectably endothermic or exothermic could occur. The thermal analysis was conducted under a dry, inert atmosphere. Therefore, the susceptibility of Form B to solvent induced transitions, including vapor induced transitions in this temperature range, also is not precluded.

Differential scanning calorimetry was performed using a Mettler Toledo 821 STAR[®] system. Samples of 3-5 mg were analyzed in aluminum crucibles with lids loosely fitted. Scans were performed from 30 to 300°C at a ramp rate of 10°C min⁻¹ under a nitrogen purge with a 40.0 ml min⁻¹ flow rate. The sample that produced the thermogram reproduced in FIG. 1 weighed 5.05 mg.

The PXRD pattern (FIG. 2) of ondansetron Form B is unique. Form B may be characterized by the PXRD characteristics set forth in Table 1 which distinguish it from Form A.

Table 1

	Peak Position (°2 θ) ^a
5	11.0
	11.2
	14.9
	15.5
	15.9
10	16.5
	20.6
	21.4
	23.1
	23.5
15	24.2
	24.7
	24.8
	25.8
	26.9
20	28.1

^a expected variation
between instruments: $\pm 1.0^\circ$.

PXRD patterns were produced on a Scintag X-ray powder diffractometer model X'TRA equipped with a copper anode tube and a solid state detector. Samples were prepared by gentle and thorough grinding in an agate mortar to reduce preferential orientation. No loss in crystallinity of samples prepared by grinding was noted. The powdered sample was poured into the round cavity of a sample holder and pressed with a glass plate to form a smooth surface. Continuous scans were run from 2 to $40^{\circ}2\theta$ at $3^{\circ} \text{ min}^{-1}$. Reported peak positions are considered accurate to within $\pm 0.05^{\circ}$. Those skilled in the art of X-ray crystallography will appreciate that peak positions determined on different instruments may vary by as much as $\pm 1^{\circ}$.

The loss on drying ("LOD") of ondansetron Form B was found to be about 2%, which is less than the amount calculated for a hypothetical hemi-hydrate (or C_1 - C_3 alcohol hemi-solvate) and is considered consistent with unsolvated ondansetron having adsorbed moisture. LOD was measured by TGA using A Mettler TG50: Sample weight: 7-15mg, heating rate: $10^{\circ}\text{C min}^{-1}$. Standard alumina crucibles were used.

Ondansetron Form B has been prepared under controlled conditions. It is only possible to describe methods which have successfully yielded Form B. Other conditions by which ondansetron Form B is produced may be found by routine experimentation.

Ondansetron Form B may be prepared by crystallizing ondansetron from a solution in a C_1 - C_3 alcohol, in particular, methanol, ethanol, propan-1-ol, propan-2-ol and mixtures thereof. Ondansetron is dissolved in the C_1 - C_3 alcohol, preferably in an amount sufficient to produce from about a 50 mM to about a 300 mM solution, more preferably from about an 85 mM to about a 150 mM solution. Ondansetron has limited solubility in these alcohols at room temperature. Consequently, it may be necessary to heat the mixture in order to fully dissolve it. Preferably, the mixture is refluxed until the mixture becomes a clear solution. The solution is preferably free of solid ondansetron that could potentially seed the mixture causing precipitation of ondansetron in a crystalline form other than Form B or co-crystallization of Form B

with another form. Preferably, the Form B obtained by crystallization from the alcohol solution contains less than or equal to about 5% other crystalline forms of ondansetron, more preferably Form B contains less than or equal to about 1% other crystalline forms of ondansetron.

5 Crystallization of Form B from the solution can occur spontaneously on standing at room temperature. If the mixture has been heated, cooling of the solution can cause supersaturation that induces crystallization of Form B. Crystallization also can be induced by seeding with a crystal of ondansetron Form B. Maximum recovery of ondansetron Form B is achieved by cooling the mixture to below ambient
10 temperature, such as from about 20°C to about 0°C. Another means of enhancing the yield of Form B is to evaporate some of the alcohol after the starting ondansetron has completely dissolved. Examples showing the use of a combination of techniques for optimal recovery of Form B are provided below. It will be noted that the preferred solution concentrations are dilute. This is a consequence of the poor solubility of
15 ondansetron in the lower alcohols from which Form B has been obtained. Cooling and/or partial evaporation of solvent is recommended to maximize recovery of the traces of dissolved ondansetron in solution after partial crystallization, though their use is not critical to practice of this invention.

 After crystallization has been deemed sufficiently complete, the crystals are
20 separated from the alcohol by conventional means such as filtration, decantation, centrifugation and the like. The crystals may be washed with solvent, such as cold methanol and dried under desiccating conditions such as 65°C under aspirator or oil pump vacuum. Yields in the 70-90% range are typical; though they may be higher or lower.

25 Ondansetron Form B can be obtained in good polymorphic purity by following the preferred embodiments of the foregoing process. Preferably ondansetron Form B prepared by that process contains less than or equal to about 5% other crystalline forms of ondansetron, more preferably less than or equal to about 1% other crystalline forms of ondansetron. Less preferred process embodiments or other processes may
30 yield ondansetron Form B in lesser degrees of purity, particularly if a seed of another

polymorph is present. Mixtures containing as little as 25% ondansetron Form B, or less, may exhibit improved properties due to the presence of Form B and, therefore, such mixtures are considered to be improved by and to fall within the scope of the present invention. Of course, ondansetron Form B that is found in mixture with other substances, like pharmaceutical excipients, even as a minor component is specifically contemplated as a material embraced by ondansetron Form B that produces a thermal analysis result indicative of a melting point of 224 ± 2 °C.

In its second aspect, the present invention provides ondansetron Form A. Form A has been characterized by PXRD, DSC and TGA using identical equipment and sample preparations as were used to characterize Form B.

Referring to FIG. 3, the differential thermogram of Form A possesses a melting endotherm with a maximum at 230°C. At temperatures higher than 230°C, there is a broad endotherm overlapping the melting endotherm that is attributed to volatilization of the ondansetron. When Form A was heated in an "open pan" the broad overlapping endotherm was not observed. However, when Form B was heated in an open pan, its DSC thermogram was the same as the thermogram observed when Form B was heated in a closed pan. The DSC thermogram of Form A was made on the same equipment and using the same procedure (but for differences noted) as were used with Form B. The sample that produced the thermogram of FIG. 3 weighed 4.75 mg.

The PXRD pattern of ondansetron Form A also clearly distinguishes it from Form B. The positions of characteristic peaks in the PXRD pattern of Form A are set forth in Table 2.

Table 2

	Peak Position	
	($^{\circ}2\theta$) ^a	
5	11.0	
	11.2	
	14.8	
	15.4	
10	16.4	
	20.6	
	21.4	
	23.2	
15	24.1	
	24.7	
	25.4	
	25.9	
20	26.7	
	27.8	
	^a expected variation between instruments: $\pm 1.0^{\circ}$.	

Beginning with the PXRD characteristics common to both Form A and Form B, there are strong peaks at 7.0, 11.0 and $11.2 \pm 1.0^{\circ} 2\theta$ and other common peaks at 14.8, 15.4, 16.5, 20.6, 21.4 and $24.2 \pm 1.0^{\circ} 2\theta$.

Significant differences between Form A and Form B are found in the 22-28 $^{\circ}$ region of the patterns. Form A produces a peak at $25.4^{\circ} 2\theta$. The peak nearest to $25.4^{\circ} 2\theta$ in the Form B pattern is at $25.8^{\circ} 2\theta$. Further, Form A has only one peak in the region of 22-24 $^{\circ}$, at $23.2^{\circ} 2\theta$. Form B produces two peaks in this region, at 23.1 and $23.5^{\circ} 2\theta$. Yet further, the peaks at 26.7 and $27.8^{\circ} 2\theta$ in the Form A pattern have no counterparts in the Form B pattern.

Lastly, a peak at $15.9^{\circ} 2\theta$ in the Form A pattern has no counterpart in the Form B pattern and a peak at $25.9^{\circ} 2\theta$ of the Form B pattern has no counterpart in the Form A pattern.

Like Form B, a sample of Form A was found to have an LOD of about 2%.

Form A has been prepared under controlled conditions. It is only possible to describe methods which have successfully yielded Form A. Other conditions by which ondansetron Form A is produced may be found by routine experimentation.

Form A may be prepared by crystallization from a wide variety of organic solvents and mixtures of organic solvents and water. Suitable organic solvents include C₄ and higher mono-, di- and polyhydroxylic alcohols; liquid aromatic compounds, such as benzene and toluene; acetic acid esters, such as ethyl acetate and butyl acetate; and polar aprotic solvents such as N,N-dimethylformamide ("DMF"). Preferred solvents are 1-butanol, ethyl acetate, butyl acetate, DMF and DMF-water mixtures. Especially preferred solvents are 1-butanol and DMF.

Ondansetron is preferably completely dissolved in the solvent before attempting to isolate Form A as a precipitate. The solubility of ondansetron in the solvent is a factor that effects the relative amounts of ondansetron and the solvent to be combined. Whereas the polarity of the solvents from which Form A can be crystallized is somewhat varied, the ratio of ondansetron to solvent varies significantly depending on solvent selection. When one of the especially preferred solvents is used, ondansetron is preferably added to the solvent in an amount sufficient to form a 50 mM to about 300 mM solution once it has completely dissolved.

Heating the mixture of ondansetron and the solvent is preferred to accelerate dissolution and increase solubility. More preferably, the mixture is heated to the reflux temperature of the solvent. Crystallization of Form A may occur spontaneously or it may be induced, for example by cooling, evaporation of solvent or seeding. A heated solution may be cooled to ambient temperature and a heated or ambient temperature solution may be cooled to low temperature, such as from 20°C to 0°C.

After crystallization of Form A is deemed sufficiently complete, the crystals are separated from the solvent by conventional means such as filtration, decantation, centrifugation and the like. The crystals may be washed with an appropriate solvent and dried by conventional techniques.

Ondansetron Form A can be obtained in good polymorphic purity by following the preferred embodiments of the foregoing process. Preferably ondansetron Form A

prepared by that process contains less than or equal to about 5% other crystalline forms of ondansetron, more preferably less than or equal to about 1% other crystalline forms of ondansetron. Less preferred process embodiments or other processes may yield ondansetron Form A in lesser degrees of purity, particularly if a seed of another polymorph is present. Mixtures containing as little as 25% ondansetron Form A, or less, may exhibit improved properties due to the presence of Form A and, therefore, such mixtures are considered to be improved by and to fall within the scope of the present invention. Of course, ondansetron Form A that is found in mixture with other substances, like pharmaceutical excipients, even as a minor component is specifically contemplated as a material embraced by ondansetron Form A.

Ondansetron Forms A and B have utility as the active agent in pharmaceutical compositions and dosage forms for prevention of nausea and vomiting associated with surgery, emetogenic cancer chemotherapy and radiotherapy. Ondansetron Forms A and B also are useful for preparing salts and solvates of ondansetron, such as the hydrochloride salt dihydrate that is currently administered to patients in the United States. To the extent that the atomic positions and molecular conformation of ondansetron do not significantly change with salt formation or solvation, such salts and solvates are considered to fall within the scope of the invention.

Ondansetron Forms A and B may be incorporated into pharmaceutical products for administration to a human or other mammal in need of suppression of vomiting. Pharmaceutical compositions and dosage forms may be formulated for transdermal delivery, enteral delivery or parenteral delivery. The most suitable route in any given case will depend on the nature and severity of the condition being treated and other circumstances that will be assessed by the caregiver. Pharmaceutical compositions for enteral delivery may be processed into tablets, powders, capsules, suppositories, sachets, troches and lozenges as well as liquid solutions, suspensions, syrups and elixirs.

Exemplary of the many excipients known to pharmacy that can be included in enteral dosage forms, there are diluents, such as microcrystalline cellulose, lactose, starch, calcium carbonate, sugar, dextrose, dibasic calcium phosphate dihydrate,

tribasic calcium phosphate, kaolin, maltodextrin and mannitol; binders such as acacia, alginic acid, carbomer, carboxymethylcellulose sodium, ethyl cellulose, gelatin, guar gum, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methyl cellulose, maltodextrin, methylcellulose, polymethacrylates, povidone and sodium alginate; disintegrants such pregelatinized starch, alginic acid, carboxymethyl cellulose calcium, croscarmellose sodium, crospovidone and sodium starch glycolate; antioxidants and chelating agents such as alcohol, sodium benzoate, butylated hydroxy toluene, butylated hydroxyanisole and ethylenediamine tetraacetic acid; antimicrobial agents such as methylparaben and propylparaben, buffers such as guconic acid, lactic acid, citric acid or acetic acid, sodium guconate, sodium lactate, sodium citrate or sodium acetate and colorants such as titanium dioxide, iron oxide yellow or iron oxide red and sweeteners and flavorings such as sucrose, aspartame and strawberry flavor.

Pharmaceutical compositions containing ondansetron Forms A and B further include oral suspensions in which the ondansetron is dispersed in a liquid vehicle, optionally with viscosity modifiers, e.g. corn syrup; antimicrobial agents, e.g. sodium benzoate; buffering agents e.g. citric acid and sodium citrate; and flavoring agents e.g. strawberry flavoring.

Such pharmaceutical products further include injectable suspensions wherein the ondansetron is suspended in an aqueous or oily medium, optionally with an antimicrobial agent, and packaged in a single dose or multi-dose container.

An especially preferred pharmaceutical dosage form of ondansetron Form A and/or Form B is an orally disintegrating tablet. Orally disintegrating tablets can be formulated according to methods known in the art using pharmaceutical excipients that disperse or dissolve in saliva and do not retain the drug in solid form. Such excipients include gelatin and mannitol, and may further include antimicrobial agents such as methylparaben and propylparaben and sweetening agents and flavoring agents such as aspartame, and strawberry flavor.

Pharmaceutical compositions and dosage forms of this invention can be administered to a patient for the purpose of preventing nausea and vomiting associated with chemotherapy and postoperative nausea or vomiting in the manner that

compositions containing known ondansetron have been administered. For this purpose, ondansetron Form A and/or Form B is administered preferably in an amount of from about 10 mg to about 50 mg per day, more preferably about 24 mg per day.

5 Having thus described the invention with respect to certain preferred embodiments, the invention will now be further illustrated with the following non-limiting examples.

EXAMPLES

Preparation of Ondansetron Form A

10 Example 1: Ondansetron (2 g) was added to N,N-dimethylformamide (80 ml). The mixture was warmed to complete dissolution. The resulting clear solution was cooled to 20°C and placed in a 2-8 °C refrigerator overnight. The next morning, the crystals were filtered off and dried at 60°C in vacuum for one day to give ondansetron Form A (0.81 g, 41%).

15 Example 2: Ondansetron (2 g) was added to 1-Butanol (30 ml). The mixture was warmed to reflux temperature. The resulting solution was cooled to 20°C and then placed in a 2-8 °C refrigerator overnight. The next morning, the crystals were filtered off and dried at 60°C under vacuum for one day to give ondansetron Form A (1.26 g, 63%).

20

Preparation of Ondansetron Form B

Example 3: Ondansetron (2 g) was added to ethanol (45 ml). The mixture was warmed to reflux temperature. The resulting clear solution was cooled to 20°C and then placed in a 2-8 °C refrigerator overnight. The next morning, the crystals were filtered off and dried at 60°C under vacuum for one day to give ondansetron Form B (1.76 g, 88 %).

25

Example 4: Ondansetron (1.5 kg) was added to methanol (60 L). The mixture was warmed to reflux temperature. The clear hot solution was filtered through carbon

30

(Norit-SX-1) . Approximately a quarter of volume of methanol was distilled off. The solution was then cooled to 0-5°C over 4 hours. The crystals were then filtered off, washed with methanol and dried at 65°C under vacuum for one day to give ondansetron Form B (1.1 kg, 73 %).

5

CLAIMS

What is claimed is:

1. A high melting crystalline form of ondansetron characterized by a thermal analysis result indicative of a melting point of 244 ± 2 °C.
2. The crystalline form of ondansetron of claim 1 wherein the thermal analysis result is a differential scanning calorimetry thermogram taken at a heating rate of 10 °C. min⁻¹ in a closed pan that exhibits a melting endotherm with a maximum at 244 ± 2 °C.
3. The crystalline form of ondansetron of claim 2 wherein the melting endotherm has a magnitude of 140 ± 10 Joules per gram.
4. The crystalline form of ondansetron of claim 1 further characterized by a powder X-ray diffraction pattern having peaks at 25.8, 26.9 and 28.1 ± 1.0 degrees two-theta.
5. The crystalline form of ondansetron of claim 4 further characterized by strong intensity peaks in the powder X-ray diffraction pattern at 15.9, 23.1, 23.5, 25.8, 26.9, and 28.1 ± 1.0 degrees two-theta and medium intensity peaks at 25.8 and 26.9 ± 1.0 degrees two-theta.
6. The crystalline form of ondansetron of claim 5 further characterized by peaks in the powder X-ray diffraction pattern at 11.0, 14.9, 15.5, 16.5, 20.6, 21.4, 24.2 ± 1.0 degrees two-theta.
7. The crystalline form of ondansetron of claim 1 containing less than or equal to about 5% other crystalline forms of ondansetron.

8. The crystalline form of ondansetron of claim 7 containing less than or equal to about 1% other crystalline forms of ondansetron.
9. A pharmaceutical composition or dosage form comprising the crystalline form of ondansetron of claim 1 and at least one pharmaceutical excipient.
10. The pharmaceutical composition or dosage form of claim 9 that is an orally disintegrating tablet.
11. A method of treating nausea and vomiting in a patient comprising administering to the patient the crystalline form of ondansetron of claim 1.
12. A process for preparing a crystalline form of ondansetron comprising:
 - a) dissolving ondansetron in an alcohol selected from the group consisting of methanol, ethanol, propan-1-ol and propan-2-ol,
 - b) crystallizing ondansetron from the alcohol under conditions effective to produce the crystalline form of ondansetron of claim 1, and
 - c) separating the crystalline form of ondansetron from the alcohol.
13. The process of claim 12 wherein dissolving produces a clear solution.
14. The process of claim 13 wherein the concentration of the solution is from about 50 mM to about 300 mM.
15. The process of claim 14 wherein separating the crystalline form of ondansetron from the alcohol comprises filtering and drying to a loss on drying of about 2 wt. %.
16. A process for preparing the crystalline form of ondansetron of claim 1 comprising:

- a) mixing ondansetron and a predetermined amount of an alcohol selected from the group consisting of methanol, ethanol, propan-1-ol and propan-2-ol
 - b) forming a solution of the ondansetron in the alcohol by application of heat, wherein the predetermined amount of alcohol is selected to produce a solution with a concentration of from about 85 mM to about 150 mM solution,
 - c) crystallizing ondansetron from the solution by cooling the alcohol to from about 0°C to about 20°C,
 - d) separating the ondansetron from the alcohol, and
 - e) drying.
17. The process of claim 16 wherein forming the solution renders the alcohol free of visible suspended solids.
 18. A crystalline form of ondansetron characterized by a powder X-ray diffraction pattern having peaks at 25.4, 26.7 and 27.8 \pm 1.0 degrees two-theta.
 19. The crystalline form of ondansetron of claim 18 further characterized by strong intensity peaks in the powder X-ray diffraction pattern at 23.2, 25.9 and 27.8 \pm 1.0 degrees two-theta and medium intensity peaks at 25.4 and 26.7 \pm 1.0 degrees two-theta.
 20. The crystalline form of ondansetron of claim 18 further characterized by peaks in the powder X-ray diffraction pattern at 11.0, 14.8, 15.5, 16.4, 20.6, 21.4, 24.2 \pm 1.0 degrees two-theta.
 21. The crystalline form of ondansetron of claim 18 containing less than or equal to about 5% other crystalline forms of ondansetron.

22. The crystalline form of ondansetron of claim 21 containing less than or equal to about 1% other crystalline forms of ondansetron.
23. The crystalline form of ondansetron of claim 18 further characterized by a thermal analysis result indicative of a melting point of $230 \pm 2^\circ\text{C}$
24. The crystalline form of ondansetron of claim 23 wherein the thermal analysis result is a differential scanning calorimetry thermogram taken at a heating rate of $10^\circ\text{C. min}^{-1}$ in a closed pan that exhibits a melting endotherm with a maximum at $230 \pm 2^\circ\text{C}$.
25. The crystalline form of ondansetron of claim 24 wherein the melting endotherm has a magnitude of 324.26 Joules per gram.
26. A pharmaceutical composition or dosage form comprising the crystalline form of ondansetron of claim 18 and at least one pharmaceutical excipient.
27. The pharmaceutical composition or dosage form of claim 26 that is an orally disintegrating tablet.
28. A method of treating nausea and vomiting in a patient comprising administering to the patient the crystalline form of ondansetron of claim 18.
29. A process for preparing a crystalline form of ondansetron comprising:
 - a) dissolving ondansetron in a solvent system selected from the group consisting of organic solvents and mixtures of organic solvent and water, wherein the organic solvent is selected from the group consisting of mono-, di-, and polyhydroxylic alcohols containing four or more carbon atoms, liquid aromatic compounds, acetic acid ester and polar aprotic solvents,

- b) crystallizing ondansetron from the alcohol under conditions effective to produce the crystalline form of ondansetron of claim 18, and
 - c) separating the crystalline form of ondansetron from the solvent.
30. The process of claim 29 wherein the organic solvent is selected from the group consisting of 1-butanol, benzene, toluene, ethyl acetate, butyl acetate and DMF.
31. The process of claim 30 wherein the organic solvent is selected from the group consisting of 1-butanol and DMF.
32. The process of claim 29 wherein dissolving produces a clear solution.
33. The process of claim 32 wherein the concentration of the solution is from about 50 mM to about 300 mM.
34. The process of claim 29 wherein the dissolving includes heating a mixture of ondansetron and the solvent.
35. The process of claim 29 wherein the crystallizing includes cooling the solution of ondansetron in the liquid medium.





FIG. 1

**FIG. 2**





FIG. 3

**FIG. 4**

INTERNATIONAL SEARCH REPORT

Intern I Application No

PCT/US 03/13220

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 C07D401/06 A61K31/473

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 C07D A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, CHEM ABS Data, BEILSTEIN Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 0 276 559 A (GLAXO GROUP LTD) 3 August 1988 (1988-08-03) example 1	1-35
X	MOOHI YOO KIM ET AL: "An Efficient Process of Ondansetron Synthesis" HETEROCYCLES, ELSEVIER SCIENCE PUBLISHERS B.V. AMSTERDAM, NL, vol. 45, no. 10, 1997, pages 2041-2043, XP002190149 ISSN: 0385-5414 page 2043, paragraph 1	18-35

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *G* document member of the same patent family

Date of the actual completion of the international search

11 August 2003

Date of mailing of the international search report

20/08/2003

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Usuelli, A

INTERNATIONAL SEARCH REPORT

In: tional application No.
PCT/US 03/13220

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

Although claims 11,28 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

☐ The additional search fees were accompanied by the applicant's protest.

☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

ation on patent family members

Interr d Application No

PCT/US 03/13220

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0276559	A	03-08-1988	AT 79031 T 15-08-1992
		AU 608794 B2	18-04-1991
		AU 8261787 A	23-06-1988
		CY 1693 A	14-01-1994
		DE 3780940 D1	10-09-1992
		DE 3780940 T2	24-12-1992
		DK 662787 A	18-06-1988
		EP 0276559 A2	03-08-1988
		ES 2051754 T3	01-07-1994
		GR 3005682 T3	07-06-1993
		HK 36593 A	23-04-1993
		IE 60135 B1	01-06-1994
		JP 2732844 B2	30-03-1998
		JP 63165314 A	08-07-1988
		NZ 222949 A	24-06-1997
		PH 25503 A	24-07-1991
		US 4835173 A	30-05-1989
		ZA 8709458 A	30-11-1988

Form PCT/ISA/210 (patent family annex) (July 1992)